1. Medtech Insight
  2. >>Device Area
  3. >>Surgery
  4. >>Surgical Procedures

The Evolving World Of Breast Cancer Management

The device industry is playing a pivotal role in the evolution toward a more personalized approach to breast cancer management, with ongoing advances in minimally invasive treatment systems, tumor characterization and breast imaging technologies adding to the momentum. In the years ahead, as the breast cancer toolbox expands, the watchword will be “choice,” with physicians and patients offered more treatment options, targeted to their specific needs and desires, than ever before.

Breast cancer management has been moving for several years now toward a more personalized approach to care – one that tailors treatment to the specific needs and desires of each patient, with the aim of providing more clinically effective and cost-effective care. That evolution is showing no signs of slowing, as researchers continue to explore many new avenues for both early detection and treatment. And, as the breast cancer toolbox expands, physicians and patients are being offered more options than ever before.

The device industry is playing a pivotal role in this shift by introducing minimally invasive therapeutic technologies and advanced imaging...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Surgical Procedures

A Decade Of Breakthrough Devices: Cardiac And Orthopedic Products Dominate FDA Designations

 
• By Brian Bossetta and Elizabeth Orr

The US FDA has provided an update on its breakthrough devices program, now 10 years running. Cardiac, orthopedic, and neurological devices have received the most designations, while only one has been awarded to an obstetrics/gynecology product.

Terumo’s $1.5Bn Buyout Of OrganOx Vaults Company Into Organ Preservation Market

 
• By Marion Webb

Terumo will acquire OrganOx for about $1.5bn, adding the only FDA-cleared liver normothermic perfusion device to its portfolio. Analysts don’t expect the buyout to have a significant impact on competition, but the deal marks a strategic shift for Terumo into transplant medicine.

SetPoint Medical Raises $140M: Pipeline Expansion And Multiple Sclerosis Clinical Trial On Horizon

 
• By Natasha Barrow

SetPoint Medical secured US FDA approval for its vagus nerve neuromodulation device to treat RA. Now, the start-up is tasked with convincing both rheumatologist and surgeons to adopt its technology over or alongside biologic drugs. CEO Murthy Simhambhatla talks exit strategy plans.

Medtronic Posts Solid First-Quarter, Adds Board Members As Elliott Takes Stake

 
• By Marion Webb

Medtronic beat first-quarter revenue and EPS estimates, raised guidance, and added two board members and special committees as Elliott takes a stake.

More from Surgery

Medtronic Posts Solid First-Quarter, Adds Board Members As Elliott Takes Stake

 
• By Marion Webb

Medtronic beat first-quarter revenue and EPS estimates, raised guidance, and added two board members and special committees as Elliott takes a stake.

Even ‘Small’ Leaks After Left Atrial Appendage Occlusion Raises Stroke Risk, Study Finds

 
• By Brian Bossetta

A Japanese study of Watchman LAA closure devices found that leaks of any size after implantation raise the risk of stroke. The study comes shortly after the US FDA issued an early alert for the Watchman access systems.

Industry Experts Expect AI-Driven Medtech M&A To Continue In 2025

 
• By Marion Webb

AI-driven medtech M&A slowed slightly in volume but tripled in value in early 2025, with buyers focusing on AI-driven diagnostics, surgical tech and analytics. Industry experts expect continued high-value deals as firms defend market share and pursue workflow-enhancing AI.